What is Hofseth BioCare ASA (HOFBF) stock price today?

Hofseth BioCare ASA (HOFBF) is currently trading at $0.17, up 0% today.

What is HOFBF P/E ratio?

Hofseth BioCare ASA's P/E ratio is -3.90. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is HOFBF return on equity (ROE)?

Hofseth BioCare ASA's return on equity (ROE) is 261.29%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Hofseth BioCare ASA's market cap?

Hofseth BioCare ASA has a market capitalization of $68.47M.

OTC · Biotechnology

Hofseth BioCare ASA (HOFBF) Stock

$0.17 +0.00% OTC: HOFBF Consumer Defensive

Valuation

Metric	Value
Price	$0.17
Market Cap	$68.47M
P/E Ratio	-3.90
P/B Ratio	-4.90
P/S Ratio	2.23
EPS (TTM)	$-0.33
52-Week High	$0.18
52-Week Low	$0.17
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	261.29%
ROA	-37.46%
ROCE	-108.22%
Gross Margin	5.33%
Operating Margin	-48.02%
Net Margin	-56.87%
Debt/Equity	-3.19
Current Ratio	0.52

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$88.0M	$120.0M	$195.0M	$257.0M	$254.0M
Operating Profit	$-119.0M	$-129.0M	$-103.0M	$-113.0M	$-113.0M
Net Profit	$-126.0M	$-137.0M	$-107.0M	$-123.0M	$-135.0M
EPS	$-0.35	$-0.37	$-0.27	$-0.30	$-0.33
Op Margin	-135.3%	-106.8%	-52.6%	-44.0%	-44.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$416.0M	$411.0M	$390.0M	$341.0M	$394.0M
Total Liabilities	$276.0M	$263.0M	$349.0M	$280.0M	$470.0M
Cash	$47.0M	$30.0M	$21.0M	$26.0M	$67.0M
Borrowings	$139.0M	$104.0M	$281.0M	$171.0M	$301.0M

Latest News

HOFSETH BIOCARE ASA: EXTRAORDINARY GENERAL MEETING COMPLETED GlobeNewswire · Jul 30, 2026 Hofseth BioCare ASA: NEW PEER-REVIEWED CLINICAL STUDY ON PROGO® PUBLISHED IN BIOMEDICINES DEMONSTRATES GLP-1 BENEFITS AND AN INCREASE LEAN MUSCLE MASS GlobeNewswire · Jul 27, 2026 HOFSETH BIOCARE ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING GlobeNewswire · Jul 9, 2026 HOFSETH BIOCARE ASA: MAJOR SHAREHOLDER NOTIFICATION GlobeNewswire · Jul 7, 2026 HOFSETH BIOCARE ASA: NEW SHARE CAPITAL REGISTERED GlobeNewswire · Jul 3, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-62.0M	$-45.0M	$3.0M	$-10.0M	$-38.0M
Investing Cash Flow	$-76.0M	$-36.0M	$-29.0M	$-8.0M	$-51.0M
Financing Cash Flow	$-21.0M	$-23.0M	$-10.0M	$-16.0M	$-17.0M
Net Cash Flow	$-123.0M	$-17.0M	$-9.0M	$2.0M	$44.0M
Free Cash Flow	$-100.0M	$-63.0M	$-11.0M	$-14.0M	$-64.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.39
EV / EBITDA	-11.47
FCF Yield	-11.62%
Quick Ratio	0.29
Interest Coverage	-4.50
Return 1Y	0.00%
Return 3Y	-83.34%
Return 5Y	-83.83%

Ownership

Insiders Held40.62%

Institutions Held13.87%

Institutions Float Held23.36%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AURXNuo Therapeutics, Inc.	$1.00	+11.11%	-20.00	$48.41M	0.00%
BXPHFBotanix Pharmaceuticals Limited	$0.02	-30.23%	-0.41	$29.89M	0.00%
HLTRFHLS Therapeutics Inc.	$2.98	+0.00%	-9.24	$93.20M	0.00%
IPHYFInnate Pharma S.A.	$1.65	+0.00%	-2.84	$154.94M	0.00%
KNTPFKintor Pharmaceutical Limited	$0.23	-0.20%	-3.33	$107.85M	0.00%

About Hofseth BioCare ASA

Hofseth BioCare ASA is a company specializing in the development and supply of premium, marine-derived ingredients for various applications in both human and animal health. Its market presence extends from Norway to an international scale. The company offers a diverse array of products. These include its general Brilliant salmon oil, alongside specialized formulations like OmeGo salmon oil, which is designed to support healthy cholesterol levels and cardiovascular function. ProGo, a rapidly absorbing salmon protein hydrolysate powder, serves as an efficient protein supplement. For bone and joint support, CalGo is a marine calcium powder developed to bolster cartilage function and promote overall joint health. Addressing beauty and wellness needs, CollaGo is a collagen peptide powder aimed at enhancing the strength and appearance of hair, skin, and nails. Rounding out their offerings is PetGo, a non-soluble protein for animal applications. Hofseth BioCare employs a multi-faceted distribution strategy, reaching customers through a network of independent distributors, agents, and its dedicated internal sales team. Furthermore, the firm maintains a significant research collaboration with the Stanford University School of Medicine. This partnership involves jointly conducting pre-clinical and clinical studies focused on conditions such as necrotizing enterocolitis and irritable bowel syndrome. Established in 2000, Hofseth BioCare ASA maintains its corporate headquarters in Ålesund, Norway.

Hofseth BioCare ASA is headquartered in NO.

Hofseth BioCare ASA (HOFBF) stock trades at $0.17 with a market capitalization of $68.47M. The stock is valued at a price-to-earnings (P/E) ratio of -3.90, price-to-book of -4.90, price-to-sales of 2.23. Over the past 52 weeks the stock has ranged between $0.17 and $0.18, and currently trades 5.6% below its 52-week high.

On profitability, Hofseth BioCare ASA generates a return on equity (ROE) of 261.29% — well above the market average, a sign of a high-quality business, return on capital employed of -108.22%, an operating margin of -48.02%, a net profit margin of -56.87%.

Official website: www.hofsethbiocare.com